Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus
Open accessAbstract
BACKGROUND: We aimed to investigate the long-term effect of metformin on the blood glucose control in non-obese patients with type 2 diabetes mellitus. METHODS: A retrospective study was performed in 213 patients with type 2 diabetes mellitus under the administration of metformin for more than one year. The clinical parameters were investigated for 3 years. The obese and non-obese individuals were defined as a body mass index (BMI) of 25 kg/m2 or over (n = 105) and a BMI of less than 25 kg/m2 (n = 108), respectively. RESULTS: HbA1c levels were significantly decreased compared with those at the baseline time. The course of HbA1c was similar between the non-obese and the obese groups, while the dose of metformin required to control blood glucose was significantly lower in the non-obese group than in the obese group. The reductions in HbA1c were 1.2% and 1.1% at 12 months, 0.9% and 0.9% at 24 months, and 0.8% and 1.0% at 36 months in the non-obese and obese groups, respectively. BMI did not change during the observation periods. Approximately half of all patients required no additional antidiabetic agents or a reduction in other treatments after the initiation of metformin in either of the two groups. CONCLUSIONS: The present study demonstrated the long-term beneficial effect of metformin in non-obese (BMI < 25 kg/m2) diabetic patients. This effect appears to be maintained even after the observation period of this study, because metformin was limited to a relatively low dose in the non-obese group and the observed worsening in glycemic control over time can probably be attenuated by increasing the dose of metformin.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Metformin has been shown to be effective in normal weight patients.
“Metformin has been also been shown to be effective in normal weight patients [19].”
From Metformin: An Old But Still the Best Treatment for Type 2 Diabetes (2013) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Revised Equations for Estimated GFR From Serum Creatinine in Japan
Matsuo, S., Imai, E., Horio, M., Yasuda, Y., Tomita, K., Nitta, K., Yamagata, K., Tomino, Y., Yokoyama, H., & Hishida, A. (2009) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2008.12.034 · Cited by 6,439 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834 · see citing works
DeFronzo, R. A. (2009) · Diabetes · doi:10.2337/db09-9028 · Cited by 3,016 · see citing works
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962 · see citing works
Coresh, J., Astor, B. C., Greene, T., Eknoyan, G., & Levey, A. S. (2002) · American Journal of Kidney Diseases · doi:10.1053/ajkd.2003.50007 · Cited by 2,761 · see citing works
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923 · see citing works
Deurenberg, P., Deurenberg‐Yap, M., & Gurrici, S. (2002) · Obesity Reviews · doi:10.1046/j.1467-789x.2002.00065.x · Cited by 1,329 · see citing works
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetologia · doi:10.1007/s00125-008-1157-y · Cited by 712 · see citing works
Efficacy of Metformin in Type II Diabetes
Garber, A. J., Duncan, T. G., Goodman, A. M., Mills, D. J., & Rohlf, J. L. (1997) · The American Journal of Medicine · doi:10.1016/s0002-9343(97)00254-4 · Cited by 519 · see citing works
(1998) · Annals of Internal Medicine · doi:10.7326/0003-4819-128-3-199802010-00001 · Cited by 385 · see citing works
Sosnowski, C., & Janeczko-Sosnowska, E. (2007) · PubMed · Cited by 234 · see citing works
Cryer, P. E. (2006) · Diabetologia · doi:10.1007/s00125-006-0448-4 · Cited by 161 · see citing works
Oba, K. (2011) · Nippon Ronen Igakkai Zasshi Japanese Journal of Geriatrics · doi:10.3143/geriatrics.48.640 · Cited by 124 · see citing works
Clarke, B. F., & Campbell, I. W. (1977) · BMJ · doi:10.1136/bmj.2.6102.1576 · Cited by 89 · see citing works
The effect of obesity on glycaemic response to metformin or sulphonylureas in Type 2 diabetes
Donnelly, L. A., Doney, A. S. F., Hattersley, A. T., Morris, A. D., & Pearson, E. R. (2006) · Diabetic Medicine · doi:10.1111/j.1464-5491.2005.01755.x · Cited by 88 · see citing works
Long-Term Efficacy of Metformin Therapy in Nonobese Individuals With Type 2 Diabetes
Ong, C. R., Molyneaux, L. M., Constantino, M., Twigg, S. M., & Yue, D. K. (2006) · Diabetes Care · doi:10.2337/dc06-0827 · Cited by 76 · see citing works
Glycemic Durability of Rosiglitazone, Metformin, or Glyburide Monotherapy
Leahy, J. L. (2007) · Yearbook of Endocrinology · doi:10.1016/s0084-3741(08)70035-0 · Cited by 67 · see citing works
Lund, S. S., Tarnow, L., Stehouwer, C. D. A., Schalkwijk, C., Frandsen, M., Smidt, U., Pedersen, O. B., Parving, H. ‐., & Vaag, A. A. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00713.x · Cited by 45 · see citing works
Lund, S. S., Tarnow, L., Frandsen, M., Nielsen, B. B., Hansen, B. V., Pedersen, O., Parving, H.-H., & Vaag, A. A. (2009) · BMJ · doi:10.1136/bmj.b4324 · Cited by 41 · see citing works
Sone, H., Tanaka, S., Iimuro, S., Oida, K., Yamasaki, Y., Oikawa, S., Ishibashi, S., Katayama, S., Ito, H., Ohashi, Y., et al. (2009) · Journal of Atherosclerosis and Thrombosis · doi:10.5551/jat.no117 · Cited by 33 · see citing works
Self-citation"Low Dose" Metformin Improves Hyperglycemia Better Than Acarbose in Type 2 Diabetics
Yajima, K., Shimada, A., Hirose, H., et al. (2004) · The Review of Diabetic Studies · doi:10.1900/rds.2004.1.89 · Cited by 15 · see citing works
Kaku, K., Tajima, N., & Kawamori, R. (2006) · 糖尿病 · Cited by 10 · see citing works
UKPDS 26: sulphonylurea failure in non-insulin-dependent diabetic patients over six years
UK Prospective Diabetes Study (UKPDS) Group, Matthews, D. R., Cull, C. A., Stratton, I. M., Holman, R. R., & Turner, R. C. (1998) · Diabetic Medicine · doi:10.1002/(sici)1096-9136(199804)15:4
Flagged first, then by citations
Cited by
Sorted by citations
Metformin: An Old But Still the Best Treatment for Type 2 Diabetes
Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · see citing works
Esfahanian, F., Zamani, M. M., Heshmat, R., & Moini nia, F. (2013) · Journal of obstetrics and gynaecology research · doi:10.1111/j.1447-0756.2012.02051.x · Cited by 38 · see citing works
- Authors
- Ito, H., Ishida, H., Takeuchi, Y., Antoku, S., Abe, M., Mifune, M., & Togane, M.
- Affiliations
- Edogawa Hospital (JP)
- Corresponding author
- Ito, Hiroyuki
- Venue
- Nutrition & Metabolism
- Published
- 2010
- Volume
- 7
- Issue
- 1
- Pages
- 83
- ISSN
- 1743-7075 (ISSN-L)
- PMC
- PMC2991324
- OpenAlex
- W2107572009
- Cited by
- 50
- References
- 26
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 2 · 2023: 3 · 2022: 6 · 2021: 8 · 2020: 1 · 2019: 1 · 2018: 3 · 2017: 6 · 2016: 3 · 2015: 1 · 2014: 4 · 2013: 5 · 2012: 2
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- Nutrition & Metabolism (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- metformin, type 2 diabetes, non-obese patients, glycemic control, HbA1c, body mass index, metformin dose
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
